Mechanism at the Gamma-Aminobutyric Acid Type A Receptor
Figure 1 — Benzodiazepine vs. Barbiturate Mechanism (Gemini)
Benzodiazepines
Increase Frequency
- Bind alpha-gamma subunit interface
- Increase frequency of chloride channel opening
- Require gamma-aminobutyric acid to be present — allosteric modulator only
- Cannot directly open channel without gamma-aminobutyric acid
- Reversed by flumazenil
Barbiturates
Increase Duration
- Bind beta subunit (separate site)
- Increase duration of chloride channel opening
- At high doses: directly open channel without gamma-aminobutyric acid
- Greater overdose danger — no ceiling effect
- No specific reversal agent
Clinical Uses
Lorazepam
- Intravenous first-line for status epilepticus
- Longer brain duration than diazepam
Diazepam
- Intravenous or rectal rescue
- Shorter brain duration due to redistribution
Clonazepam
- Oral chronic use
- Myoclonic and absence seizures
- Tolerance limits long-term use
Phenobarbital
Key Clinical Facts
- First-line for neonatal seizures
- Third-line in status epilepticus (after benzodiazepines and second-line agents fail)
- Cytochrome P450 inducer — broad drug interactions
- Sedation and cognitive impairment often treatment-limiting
- Primidone is metabolized to phenobarbital — essentially the same drug clinically
Status Epilepticus Protocol
Figure 2 — Status Epilepticus Treatment Steps (Gemini)
Overdose Safety Rule
Benzodiazepine overdose is reversible with flumazenil. Barbiturate overdose has no reversal agent — treatment is supportive only. This safety asymmetry is why benzodiazepines replaced barbiturates for anxiety and insomnia, despite barbiturates being introduced first.